Literature DB >> 24574038

Tracking CF disease progression with CT and respiratory symptoms in a cohort of children aged 6-19 years.

Leonie A Tepper1, Daan Caudri, Elisabeth M W J Utens, Els C van der Wiel, Alexandra L Quittner, Harm A W M Tiddens.   

Abstract

INTRODUCTION: Cystic fibrosis (CF) lung disease is characterized by bronchiectasis and trapped air on chest computed tomography (CT).
OBJECTIVE: We aim to validate bronchiectasis and trapped air as outcome measures by evaluating associations between changes in bronchiectasis, trapped air and patient-reported respiratory symptoms.
METHODS: A longitudinal cohort study has been conducted. CF patients (aged 6-19 years) who had two routine CTs and completed twice a Cystic Fibrosis Questionnaire-Revised within 2 years (referred to as T1 and T2 ), in the period of July 2007 to January 2012 were included. Bronchiectasis and trapped air were scored using the CF-CT scoring system. Correlation coefficients and student's paired t tests were performed.
RESULTS: In total 40 patients were included with a median age at T1 of 12.6 years (range 6-17 years), and at T2 14.5 years (range 8-19 years). At T1 , bronchiectasis (r = -0.49, P < 0.01) and trapped air (r = -0.34, P = 0.04) correlated with CFQ-R Respiratory Symptoms Scores (CFQ-R RSS). At T2 similar correlations were found with the CFQ-R RSS. Over 2 years, there was significant progression in bronchiectasis (P = 0.03) and trapped air (P = 0.03), but not in CFQ-R RSS. Changes in bronchiectasis and trapped air were not associated with changes in CFQ-R RSS.
CONCLUSION: Our results indicate that bronchiectasis and trapped are sensitive outcome measures in CF lung disease, showing a significant association with CFQ-R RSS at two-time points. However, progression of bronchiectasis and trapped air over 2 year does not necessarily correlate to changes in quality of life.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  imaging; outcome measures; quality of life; validation

Mesh:

Year:  2014        PMID: 24574038     DOI: 10.1002/ppul.22991

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  6 in total

Review 1.  Chest imaging in cystic fibrosis studies: What counts, and can be counted?

Authors:  Rhonda Szczesniak; Lidija Turkovic; Eleni-Rosalina Andrinopoulou; Harm A W M Tiddens
Journal:  J Cyst Fibros       Date:  2016-12-28       Impact factor: 5.482

2.  Quantification of Cystic Fibrosis Lung Disease with Radiomics-based CT Scores.

Authors:  Guillaume Chassagnon; Evangelia I Zacharaki; Sébastien Bommart; Pierre-Régis Burgel; Raphael Chiron; Séverine Dangeard; Nikos Paragios; Clémence Martin; Marie-Pierre Revel
Journal:  Radiol Cardiothorac Imaging       Date:  2020-12-17

3.  An automated computed tomography score for the cystic fibrosis lung.

Authors:  Guillaume Chassagnon; Clémence Martin; Pierre-Régis Burgel; Dominique Hubert; Isabelle Fajac; Nikos Paragios; Evangelia I Zacharaki; Paul Legmann; Joel Coste; Marie-Pierre Revel
Journal:  Eur Radiol       Date:  2018-06-04       Impact factor: 5.315

4.  Diagnosis of bronchiectasis and airway wall thickening in children with cystic fibrosis: Objective airway-artery quantification.

Authors:  Wieying Kuo; Marleen de Bruijne; Jens Petersen; Kazem Nasserinejad; Hadiye Ozturk; Yong Chen; Adria Perez-Rovira; Harm A W M Tiddens
Journal:  Eur Radiol       Date:  2017-05-18       Impact factor: 5.315

5.  Airway disease on chest computed tomography of preschool children with cystic fibrosis is associated with school-age bronchiectasis.

Authors:  Nynke R Bouma; Hettie M Janssens; Eleni-Rosalina Andrinopoulou; Harm A W M Tiddens
Journal:  Pediatr Pulmonol       Date:  2019-09-09

6.  Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: Lessons learned from the first ataluren phase 3 study.

Authors:  Harm A W M Tiddens; Eleni-Rosalina Andrinopoulou; Joe McIntosh; J Stuart Elborn; Eitan Kerem; Nynke Bouma; Jochem Bosch; Mariette Kemner-van de Corput
Journal:  PLoS One       Date:  2020-11-03       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.